Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. (Q50513904)

14 March 2018

title

Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. (English)

1 reference

14 March 2018

Gunilla Westergren-Thorsson

1 reference

7

object named as

Gunilla Westergren-Thorsson

1 reference

14 March 2018

Kristina Rydell-Törmänen

1

1 reference

14 March 2018

Kristofer Andréasson

2

1 reference

14 March 2018

Roger Hesselstrand

3

1 reference

14 March 2018

Juha Risteli

4

1 reference

14 March 2018

Dick Heinegård

5

1 reference

14 March 2018

Tore Saxne

6

1 reference

14 March 2018

publication date

2 April 2012

1 reference

14 March 2018

published in

Laboratory Investigation

1 reference

14 March 2018

volume

92

1 reference

14 March 2018

issue

6

1 reference

14 March 2018

page(s)

917-925

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1038/labinvest.2012.57

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

The respiratory system in connective tissue disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Cellular and molecular mechanisms of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Murine models of pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Animal models of acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Direct evidence of secondary necrosis of neutrophils during intense lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

The definition of fibrogenic processes in fibroblastic foci of idiopathic pulmonary fibrosis based on morphometric quantification of extracellular matrices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Fibroblasts and myofibroblasts: what are we talking about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Pulmonary toxicity of bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Bleomycins: towards better therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

Extracellular matrix proteins and myofibroblasts in granulomas of sarcoidosis, atypical mycobacteriosis, and tuberculosis of the lung

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.57

7 January 2021

10.1038/LABINVEST.2012.57

Identifiers

DOI

1 reference

14 March 2018

PubMed ID

22469699

1 reference

14 March 2018